Latin America Cancer Hormone Therapy Market (2021–2031)

The Latin America cancer hormone therapy market size is expected to reach US$ 3,091.7 million by 2031 from US$ 1,641.9 million in 2024. The market is estimated to record a CAGR of 9.5% from 2025 to 2031.

Executive Summary and Latin America Cancer Hormone Therapy Market Analysis:

Hormone therapy has become an important option for managing hormone-sensitive cancers, particularly breast and prostate cancers, as awareness of these conditions improves among both patients and healthcare professionals. Growth in the market is driven by expanding diagnostic capabilities, wider adoption of international treatment guidelines, and strengthening public healthcare programs focused on cancer management. Urbanization and the concentration of specialized oncology centers in major cities have supported the integration of hormone therapy into routine clinical practice.

Uneven access to specialized cancer care across countries and within rural areas limits widespread hormone therapy utilization. Public healthcare budget constraints and reimbursement challenges affect the availability of advanced hormone treatments, leading to variability in treatment options across the region. The reliance on imported oncology drugs can create supply chain and pricing pressures. Despite these challenges, ongoing healthcare reforms, growing private sector participation, and increasing collaboration with global pharmaceutical companies are improving access to hormone therapies, supporting the sustained development of the market.

Latin America Cancer Hormone Therapy Market - Strategic Insights:

Latin America Cancer Hormone Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the Latin America cancer hormone therapy market analysis are drug class, cancer type, route of administration, and sales channel.

• By drug class, the cancer hormone therapy market is segmented into GnRH analogs, GnRH antagonists, androgen receptor antagonists, aromatase inhibitors, selective estrogen receptor modulators, estrogen receptor antagonists, thyroid hormone therapy, and others. The GnRH analogs segment dominated the market in 2024.
• By cancer type, the cancer hormone therapy market is segmented into breast cancer, prostate cancer, endometrial cancer, ovarian cancer, thyroid cancer, and others. The breast cancer segment dominated the market in 2024.
• By route of administration, the cancer hormone therapy is segmented into oral, injectable, and implantable. The oral segment dominated the market in 2024.
• By sales channel, the cancer hormone therapy market is segmented into hospitals, cancer treatment centers, specialty clinics, and retail pharmacies. The hospitals segment dominated the market in 2024.

Latin America Cancer Hormone Therapy Market Drivers and Opportunities:

Hormone-Responsive Cancers: A Growing Health Concern

Latin America is experiencing a growing burden of hormone-responsive cancers, driven by demographic aging, urbanization, and changing lifestyle patterns. Breast cancer is the most frequently diagnosed malignancy among women across the region, with hormone receptor–positive (HR+) disease representing a substantial share of cases. Prostate cancer is a leading cancer among men, particularly in countries such as Brazil, Argentina, Mexico, and Chile, where increased life expectancy and improved diagnostic awareness are contributing to higher detection rates. These trends position hormone therapy as a central component of cancer care throughout Latin America.

 In countries with more developed healthcare systems, such as Chile, Uruguay, and parts of Brazil, organized screening programs support earlier detection and prolonged use of adjuvant endocrine therapy. Elsewhere, delayed diagnosis remains common, resulting in higher reliance on systemic hormone therapy for advanced disease. Public health systems shoulder the majority of care, while private oncology centers in major cities provide access to more comprehensive endocrine treatment pathways.

In addition to breast and prostate cancer, other hormone-sensitive tumors, including select gynecologic cancers, contribute to endocrine therapy utilization. Gradual expansion of pathology and hormone receptor testing capacity is improving patient identification, although access remains uneven in rural and underserved areas.

Combination Regimens: A Growing Treatment Trend

Combination hormone therapy regimens are adopted in Latin American oncology practice, particularly for patients with advanced or high-risk disease. In HR+ breast cancer, endocrine agents such as aromatase inhibitors or selective estrogen receptor modulators are often combined with ovarian suppression or additional systemic therapies to enhance treatment effectiveness. Academic centers and specialized cancer institutes in Brazil, Argentina, and Mexico are leading the integration of these combination strategies into routine care.

Prostate cancer management across the region reflects growing use of combination approaches. Androgen deprivation therapy remains the treatment backbone, but it is paired with other hormonal agents or systemic therapies for metastatic or recurrent disease. While access varies between public and private sectors, regional clinical guidelines and physician training initiatives are supporting broader adoption of combination regimens aligned with international standards.

The expansion of combination hormone therapy is reinforced by regional collaboration, professional education, and the gradual harmonization of treatment protocols. Multidisciplinary tumor boards and cross-institutional networks are improving consistency of care, even amid healthcare system constraints. Combination hormone therapy is becoming a sophisticated element of cancer treatment across Latin America.

Latin America Cancer Hormone Therapy Market Size and Share Analysis:

The Latin America cancer hormone therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within drug class, cancer type, route of administration, and sales channel, highlighting their respective contributions to overall market performance.

By drug class, the GnRH analogs subsegment dominated the market in 2024. Their proven efficacy in hormone-dependent cancers, widespread clinical adoption, established safety profile, and ability to effectively suppress gonadotropin release make them a cornerstone of endocrine-based cancer therapies.

Per cancer type, the breast cancer subsegment dominated the market in 2024, driven by the high global prevalence of breast cancer, increasing awareness and screening programs, strong reliance on hormone-based treatments, and continuous advancements in targeted and combination therapies.

By route of administration, the oral subsegment dominated the market in 2024. Oral therapies are preferred due to their ease of administration, improved patient compliance, convenience for long-term treatment, reduced need for hospital visits, and growing availability of effective oral oncology drugs.

Per sales channel, the hospitals subsegment dominated the market in 2024. Hospitals remain the primary distribution channel as they offer comprehensive cancer care, access to specialized oncology pharmacists, advanced treatment infrastructure, and integrated diagnostic and therapeutic services, ensuring efficient delivery of cancer medications.

Latin America Cancer Hormone Therapy Market Report Highlights:

Latin America Cancer Hormone Therapy Market Report Coverage and Deliverables:

The "Latin America Cancer Hormone Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Latin America Cancer Hormone Therapy market size and forecast at regional and country levels for all the key market segments covered under the scope
• Latin America Cancer Hormone Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Latin America Cancer Hormone Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Latin America Cancer Hormone Therapy market
• Detailed company profiles, including SWOT analysis

Latin America Cancer Hormone Therapy Market Geographic Insights:

The geographical scope of the Latin America Cancer Hormone Therapy market report is divided into: Brazil, Mexico, Argentina, Colombia, Chile, and Peru. Brazil held the largest share in 2024.

Brazil dominates the market due to its advanced healthcare infrastructure and expanding focus on oncology services. The country has made progress in integrating hormone therapy into standardized cancer treatment protocols, particularly within public hospitals and specialized cancer institutions. Growing awareness of early cancer detection and improved referral pathways has increased the role of hormone therapies as part of comprehensive cancer management strategies. Brazil’s large urban centers serve as hubs for oncology care, where access to trained specialists and diagnostic facilities supports consistent use of hormone-based treatments.

The presence of multinational and regional pharmaceutical companies strengthens Brazil’s hormone therapy landscape, enabling wider availability of established and emerging therapies. Public health initiatives aimed at improving cancer care access have encouraged the adoption of hormone therapy, especially for long-term disease management. Nonetheless, challenges remain in addressing disparities between urban and rural healthcare access and ensuring consistent reimbursement across healthcare systems. Continued investment in oncology infrastructure, professional training, and policy alignment is expected to reinforce Brazil’s leadership in the market.

Latin America Cancer Hormone Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the Latin America cancer hormone therapy market across drug class, cancer type, route of administration, sales channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Latin America Cancer Hormone Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Latin America Cancer Hormone Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Latin America Cancer Hormone Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover Latin America Cancer Hormone Therapy market segments by drug class, cancer type, route of administration, sales channel, and geography across Brazil, Mexico, Argentina, Colombia, Chile, and Peru. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Latin America Cancer Hormone Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

Latin America Cancer Hormone Therapy Market News and Key Development:

The Latin America Cancer Hormone Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Latin America cancer hormone therapy market are:

• In March 2025, Telix Pharmaceuticals Limited announced that the Brazilian Health Regulatory Agency (ANVISA) approved Illuccix — a gallium-68 PSMA PET imaging agent for prostate cancer — and that its partner R2PHARMA will manufacture, distribute, and commercialize Illuccix across Brazil and Latin America, strengthening regional diagnostics and treatment support infrastructure; while this is imaging-focused, improved prostate cancer management supports broader oncology care ecosystems that include hormone receptor-driven cancers.
• In March 2024, Shanghai Henlius Biotech announced that its trastuzumab biosimilar HANQUYOU was approved for marketing in Brazil for the treatment of HER2-positive breast cancer and gastric cancer, marking an expansion of this biologic therapy’s availability in Latin America’s largest market.

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• American Association for Cancer Research (AACR)
• National Cancer Institute (NCI)
• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• Company Websites
• Company Annual Reports
• Company Investor Presentations